Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
It is intended for contrast enhancement in MRI scans
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Subscribe To Our Newsletter & Stay Updated